XML 12 R2.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
Sep. 30, 2025
Dec. 31, 2024
Assets [Abstract]    
Land $ 16,625,237 $ 15,983,323
Buildings and improvements 105,024,265 102,862,977
Tenant improvements 17,338,795 16,488,066
Lease intangibles 3,475,531 3,776,654
Real estate assets and lease intangibles held for investment, cost 142,463,828 139,111,020
Accumulated depreciation and amortization (36,622,641) (33,700,262)
Real estate assets and lease intangibles held for investment, net 105,841,187 105,410,758
Real estate assets held for sale, net 7,440,774 22,185,742
Real estate assets, net 113,281,961 127,596,500
Other assets:    
Cash, cash equivalents and restricted cash 8,002,915 8,036,496
Deferred leasing costs, net 1,378,568 1,666,135
Goodwill 1,389,000 1,389,000
Investment in Conduit Pharmaceuticals marketable securities (see Notes 2 & 9) 7,515 206,177
Deferred tax asset 298,645 298,645
Other Assets, Miscellaneous 3,450,281 3,376,697
Total other assets 14,526,924 14,973,150
TOTAL ASSETS (1) [1] 127,808,885 142,569,650
Liabilities:    
Mortgage notes payable, net 83,277,135 80,977,448
Mortgage notes payable related to properties held for sale, net 10,442,278 21,116,646
Mortgage notes payable, total net 93,719,413 102,094,094
Accounts payable and accrued liabilities 3,043,157 3,290,170
Accrued real estate taxes 1,457,629 1,972,477
Dividends payable - Series D Preferred Stock 190,393 194,784
Lease liability, net 46,373 64,345
Below-market leases, net 4,560 8,625
Total liabilities 98,461,525 107,624,495
Commitments and contingencies (see Note 10)
Equity:    
Additional paid-in capital 186,477,510 185,770,842
Dividends and accumulated losses (165,400,881) (159,374,010)
Total stockholders' equity before noncontrolling interest 21,098,683 26,535,146
Noncontrolling interest 8,248,677 8,410,009
Total equity 29,347,360 34,945,155
TOTAL LIABILITIES AND EQUITY 127,808,885 142,569,650
Series D Preferred Stock [Member]    
Equity:    
Series D Preferred Stock, $0.01 par value per share; 1,000,000 shares authorized; 974,823 shares issued and outstanding (liquidation preference $25.00 per share) as of September 30, 2025 and 997,082 shares issued and outstanding as of December 31, 2024 9,748 9,971
Common Class A [Member]    
Equity:    
Series A Common Stock, $0.01 par value per share, shares authorized: 100,000,000; 1,230,601 shares and 1,283,432 shares were issued and outstanding as of September 30, 2025 and December 31, 2024, respectively $ 12,306 $ 128,343
[1] As of June 30, 2025 and December 31, 2024, includes approximately $9.9 million and $11.4 million, respectively, of assets related to consolidated variable interest entities that can be used only to settle obligations of the consolidated variable interest entities.